EGA
GNCA

Eagle Global Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Eagle Global Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,346
Closed -$83K – 408
2016
Q1 		$83K Buy
+1,346
New +$42.7K ﹤0.01% 356

Other funds holding GNCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Eagle Global Advisors's GNCA Position: Q2 2016 in Review

Eagle Global Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2016, closing a stake of 1,346 shares — an estimated $83K sold.

Eagle Global Advisors first reported a position in GNCA in Q1 2016 and held it in 1 quarter. The position peaked at $83K in Q1 2016. 57 funds tracked by Wall St. Rank hold GNCA as of Q2 2016.

  • Eagle Global Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2016 after selling out during the quarter.
  • Eagle Global Advisors sold 1,346 Genocea Biosciences, Inc. shares in Q2 2016, an estimated $83K.
  • Eagle Global Advisors first reported a position in Genocea Biosciences, Inc. in Q1 2016 and held it in 1 quarter.
  • Eagle Global Advisors's Genocea Biosciences, Inc. position peaked at $83K in Q1 2016.
  • 57 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2016.

Based on Eagle Global Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.